The STARLING trial is evaluating the combination of TBio-4101 (TIL) and pembrolizumab, while another trial currently recruiting is combining L-TIL plus tislelizumab for PD1 antibody-resistant NSCLC (NCT05576077 and NCT05878028, respectively) [96,97]. Here, PDCD1 is linked to non-small cell lung carcinoma.